RPG Life Sciences · NSE: RPGLIFE · BSE: 532983
Q4 FY26 results · Jan–Mar 2026
RPG Life Sciences reported revenue from operations of ₹176.89 crore and net profit of ₹29.90 crore for Q4 FY26 (Jan–Mar 2026), on a consolidated basis.
| Item | Q4 FY26 | Q4 FY25 | YoY | Q3 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 176.89 | — | — | 180.03 | −1.7% |
| Other income | 12.40 | — | — | 3.41 | +263.6% |
| Total income | 189.29 | — | — | 183.44 | +3.2% |
| Profit before tax | 40.20 | — | — | 29.12 | +38.0% |
| Net profit for the period | 29.90 | — | — | 22.13 | +35.1% |
| EPS, basic (₹) | 18.08 | — | — | 13.38 | not comparable |
| Net margin (%) | 16.9 | — | 12.3 |
| Item | Q4 FY26 | Q4 FY25 | YoY | Q3 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 176.89 | 143.09 | +23.6% | 180.03 | −1.7% |
| Other income | 12.36 | 5.06 | +144.3% | 3.41 | +262.5% |
| Total income | 189.25 | 148.15 | +27.7% | 183.44 | +3.2% |
| Profit before tax | 40.20 | 134.90 | −70.2% | 29.12 | +38.0% |
| Net profit for the period | 29.90 | 117.35 | −74.5% | 22.13 | +35.1% |
| EPS, basic (₹) | 18.08 | 70.96 | −74.5% | 13.38 | not comparable |
| Net margin (%) | 16.9 | 82.0 | 12.3 |
Consolidated
- Filed with BSE
- 29 Apr 2026, 23:19 IST
- Board meeting
- 29 Apr 2026
- Period
- 01 Jan 2026 to 31 Mar 2026
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 29 Apr 2026, 23:19 IST
- Board meeting
- 29 Apr 2026
- Period
- 01 Jan 2026 to 31 Mar 2026
- Review status
- Audited
- Source
- XBRL filing on BSE